What Is Cobenfy? Uses, Dosage, and What You Need to Know in 2026

Cobenfy is a prescription medication approved by the FDA in September 2024 for the treatment of schizophrenia in adults. It is a landmark drug in psychiatry — the first new mechanism of action for schizophrenia in more than 30 years, and the only schizophrenia treatment that does not work by blocking dopamine. This comprehensive guide covers everything you need to know about Cobenfy in 2026.

What Is Cobenfy?

Cobenfy is the brand name for xanomeline and trospium chloride — a fixed-dose combination of two drugs taken together in a single capsule. It was developed by Karuna Therapeutics (formerly known as KarXT in clinical trials) and is now marketed by Bristol Myers Squibb, which acquired Karuna for $14 billion in March 2024. Cobenfy is classified as a muscarinic agonist/antagonist combination, a completely new drug class for psychiatry.

What Does Cobenfy Treat?

Cobenfy is FDA-approved for one indication: the treatment of schizophrenia in adults. It is not currently approved for pediatric use, bipolar disorder, depression, or any other condition. Schizophrenia affects approximately 2.8 million adults in the United States and is characterized by three types of symptoms:

• Positive symptoms — hallucinations (hearing voices), delusions, disorganized thinking and speech
• Negative symptoms — lack of motivation, flat affect (limited emotional expression), social withdrawal
• Cognitive dysfunction — impaired memory, attention, and decision-making

In clinical trials (EMERGENT-2 and EMERGENT-3), Cobenfy significantly reduced both positive and negative symptoms of schizophrenia compared to placebo, as measured by the PANSS (Positive and Negative Syndrome Scale) total score.

How Is Cobenfy Different from Other Schizophrenia Medications?

Every other FDA-approved antipsychotic medication works by blocking dopamine D2 receptors in the brain. This approach has been the standard since the 1950s. Cobenfy is the first approved drug to take a completely different approach — instead of blocking dopamine, it activates muscarinic acetylcholine receptors (M1 and M4). This different mechanism leads to a different side effect profile: Cobenfy is NOT associated with the weight gain, movement disorders (EPS), or hormonal changes (prolactin elevation) common with older antipsychotics.

Cobenfy is also notable for NOT having an FDA black box warning — it is the only schizophrenia medication without one.

What Is the Dosage of Cobenfy?

Cobenfy comes in three capsule strengths, taken orally twice daily (BID):

• 50 mg xanomeline / 20 mg trospium chloride — starting dose (take for at least 2 days)
• 100 mg / 20 mg — intermediate dose (take for at least 5 days)
• 125 mg / 30 mg — target maintenance dose (if tolerated); maximum dose is 250 mg/60 mg per day

In clinical trials, 87% of patients successfully increased to the 125 mg/30 mg BID maintenance dose. For elderly patients, the maximum dose is 100 mg/20 mg BID with a slower titration.

How Do You Take Cobenfy?

Key instructions for taking Cobenfy:

• Take on an empty stomach — at least 1 hour BEFORE eating or at least 2 hours AFTER eating. Food significantly increases GI side effects.
• Do NOT open, crush, or chew the capsules — swallow them whole
• Take at the same times each day to keep a steady level in your body
• Store at room temperature (68–77°F / 20–25°C)

Is Cobenfy a Controlled Substance?

No. Cobenfy is not a controlled substance. It does not have abuse potential and does not require special DEA scheduling. This also means it can be prescribed via telehealth without the additional restrictions that apply to controlled substances, and it does not require a REMS (Risk Evaluation and Mitigation Strategy) program like clozapine does.

How Much Does Cobenfy Cost?

The list price is approximately $1,887/month. There is no generic version. However, most patients pay significantly less. Eligible commercially insured patients may pay as little as $0/month with the COBENFY Cares co-pay program. Medicare patients using Extra Help pay as low as $12.15/month. Read our full guide to saving money on Cobenfy for all cost reduction options.

Who Should Not Take Cobenfy?

Cobenfy is contraindicated in patients with: pre-existing urinary retention, moderate or severe liver disease, gastric retention (stomach that does not empty properly), a prior allergic reaction to Cobenfy or trospium chloride, or untreated narrow-angle glaucoma. It is also not recommended in patients with significant kidney problems (eGFR below 60 mL/min) or active gallbladder disease.

Where Can I Get Cobenfy?

Cobenfy requires a prescription from a psychiatrist or other licensed prescriber. Once prescribed, it is available at specialty pharmacies and some retail chains. Use Medfinder.com to find which pharmacies near you have it in stock.